We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
iCo Therapeutics Completes iCo-007 Phase 2 Clinical Supply Manufacturing
News

iCo Therapeutics Completes iCo-007 Phase 2 Clinical Supply Manufacturing

iCo Therapeutics Completes iCo-007 Phase 2 Clinical Supply Manufacturing
News

iCo Therapeutics Completes iCo-007 Phase 2 Clinical Supply Manufacturing

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "iCo Therapeutics Completes iCo-007 Phase 2 Clinical Supply Manufacturing"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

iCo Therapeutics Inc. has announced the completion of drug product manufacturing activities as part of its Phase 2 clinical program investigating multiple doses and injections of iCo-007 in patients with diabetic macular edema (DME). Currently the market for this unmet medical condition is estimated to be US $800 million to US $1 billion in the United States alone.

iCo is evaluating potential clinical activities in several regulatory jurisdictions, including Canada, where the Company has received a No Objection Letter from Health Canada's Therapeutic Products Directorate related to its submitted Phase 2 DME clinical trial plan.

"We are pleased to have completed this critical stage," stated Andrew Rae, iCo's President & CEO. "An impressive array of clinicians from multiple clinical sites have been identified and solicited for their inputs and potential involvement in our next stage of development. iCo also continues to build strong relationships with philanthropic organizations and advocacy groups as a means of maximizing the potential data derived from the iCo-007 program but also return on capital to our shareholders.

Advertisement